Скачать или смотреть Satellos (MSCL) - Presentation, Deep Dive and Q&A with CEO Frank Gleeson

Satellos (MSCL) Presentation, Deep Dive and Q&A with CEO Frank Gleeson

https://satellos.com/
Satellos Bioscience Inc. (TSXV: MSCL) (OTC: MSCLF)
Satellos is a biotechnology company dedicated to developing life-changing medicines that have the potential to correct a previously unrecognized root cause of degenerative muscle disorders which its scientists have identified. Satellos was established in 2018 to translate the groundbreaking discoveries of its scientific founder, Dr. Michael Rudnicki, a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. Satellos's lead program is focused on developing an oral therapeutic drug (that is, a pill) to treat Duchenne muscular dystrophy where Satellos has shown that the body's muscle stem cells do not produce enough muscle cell progenitors to keep up with the continuous damage caused by the disorder. The company's drug development work offers hope for people living with Duchenne that a drug may have the potential to reset the body's innate ability to repair and grow muscle. To expand its programs, Satellos has created a proprietary discovery platform, MyoReGenX, to identify other muscle disorders where deficits in muscle stem cell regeneration can be addressed with drug treatment.


0:00:00 Opening & Disclaimers
0:00:13 Intro
0:01:00 Presentation
0:15:00 Part 2
0:30:00 Part 3
0:45:00 Part 4